Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study

References

• Thaçi D. Long-term data in the treatment of psoriasis. Br J Dermatol. 2008;159:18–24.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Körber A, Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34(2):310–318.
   PubMed Web of Science ®Google Scholar
• Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol. 2017;76(4):662–669.e1.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183:1–9.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, van Vugt LJ, van Doorn MBA, et al. Initial results of secukinumab drug survival in patients with psoriasis: a multicentre daily practice cohort study. Acta Derm Venereol. 2018;98(7):648–654.
   PubMed Web of Science ®Google Scholar
• Lunder T, Zorko MS, Kolar NK, et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol. 2019;58(6):631–641.
   PubMed Web of Science ®Google Scholar
• Emery P, Vlahos B, Szczypa P, et al. Longterm drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2020;47(4):493–501.
   PubMed Web of Science ®Google Scholar
• Kromer C, Wilsmann-Theis D, Gerdes S, et al. Drug survival und Gründe für einen Therapieabbruch bei Pustulosis palmoplantaris: Eine retrospektive multizentrische Studie. J Dtsch Dermatol Ges. 2019;17:503–517.
   Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Lee EB, Amin M, Egeberg A, et al. Drug survival of secukinumab for psoriasis in a real-world setting. J Dermatolog Treat. 2019;30(2):150–151.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Puig L, Lõpez A, Vilarrasa E, et al. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol. 2014;28(12):1633–1653.
   PubMed Web of Science ®Google Scholar
• Pogácsás L, Borsi A, Takács P, et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatolog Treat. 2017;28(7):635–641.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Mezzarobba M, Weill A, et al. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180(1):86–93.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, Zweegers J, Kievit W, et al. 'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014;171(5):1189–1196.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nobeyama Y, Hayashi M, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40(12):1008–1013.
   PubMed Web of Science ®Google Scholar
• Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8:1–7.
   PubMed Web of Science ®Google Scholar
• Marinas JEC, Kim WB, Shahbaz A, et al. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: a Canadian multicentre retrospective study. Aust J Dermatol. 2018;59(1):e11–e14.
   PubMed Web of Science ®Google Scholar
• Arnold T, Schaarschmidt ML, Herr R, et al. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14:1090–1101.
   PubMed Web of Science ®Google Scholar
• Vilarrasa E, Notario J, Bordas X, et al. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74(6):1066–1072.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;81(1):173–178.
   PubMed Web of Science ®Google Scholar
• Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81:273–275.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. Int J Dermatol. 2016;55(3):296–302.
   PubMed Web of Science ®Google Scholar